Diabetic Kidney Disease, Diabetes Mellitus, Type 2, Diabetic Nephropathies
Conditions
Keywords
N-Acetyl cysteine, Lipoprotein a, Triglycerides, Total cholesterol, Glycated Haemoglobin, Fasting blood sugar, Serum creatinine, Blood urea nitrogen, Urine analysis, High density lipoprotein, Low density lipoprotein
Brief summary
The study is focused on the possible improving effect of N-acetylcysteine on nephropathy of type-2 diabetic patients. Study design: Prospective clinical based study. The aim of this work is to study the effect of N-acetylcysteine (NAC) on proteinuria and on the serum level of lipoprotein a (LPa) in diabetes induced nephropathy in type-2 diabetic patients.
Detailed description
This study will be carried on 60 participants with Type 2 Diabetes with age over 20 years. Participants will be classified into two groups: 1. Group I (Interventional): treated with (NAC) dose of 1200 mg/day for two months in conjunction with conventional treatment. 2. Group II (Non-interventional): control group receive conventional treatment. All patients will undergo the following: 1. Full medical history will be taken. 2. Laboratory investigations as follows: Blood samples will be collected for analysis after overnight fasting at the beginning and after 2 months of the study for determination of: 1. Total cholesterol (T-chol). 2. Plasma triglycerides (TG). 3. High density lipoprotein cholesterol (HDL-C). 4. Low density lipoprotein cholesterol (LDL-C). 5. Fasting blood sugar. 6. Blood urea nitrogen (BUN). 7. Serum creatinine (SCr). 8. Urine analysis. 9. Glycated hemoglobin (HbA1c). 10. Lipoprotein (a). In addition, blood pressure will be measured for 24 hr.
Interventions
DRUGN Acetylcysteine
(NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.
Sponsors
Al-Azhar University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
All participants,investigators, care providers, and outcome assessor have knowledge of the interventions assigned to individual participants.
Intervention model description
Two arms are being used parallel to each other at the same time. Participants are assigned to two groups in parallel for the duration of the study. One arm is interventional assigned to drug administration and the other is a control arm.
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1. Confirmed diagnosis of Diabetes Mellitus. 2. Age over 20 years. 3. Patients with proteinuria ≥ 30 mg /dl.
Exclusion criteria
1. Patients on lipid lowering medications. 2. Cigarette smokers. 3. Presence of liver and heart diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Lipoprotein (a) | 2 months | unique lipoprotein that has emerged as an independent risk factor for developing vascular disease. |
| Triglycerides | 2 months | Triglycerides are a type of fat (lipid) found in our blood. It is one of the lipid panel used to determine atherosclerotic risk that contributes to vascular diseases. |
| Systolic blood pressure | 2 months | The first number of blood pressure reading and it indicates how much pressure our blood is exerting against our artery walls when the heart beats. It is a major risk factor for cardiovascular disease. |
Countries
Egypt
Outcome results
None listed